ADNI is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). The ADNI study began in 2004 and included 400 subjects diagnosed with mild cognitive impairment (MCI), 200 subjects with early AD and 200 elderly control subjects.
The six-year study was funded by $67 million provided by both the public and private sectors. Financial support came from the National Institute on Aging, 13 pharmaceutical companies and two foundations that provided funding through the Foundation for the National Institutes of Health. This initial phase of the study is known as ADNI1.
In 2009, ADNI1 was extended with ADNI GO which assessed the existing ADNI1 cohort and added 200 participants identified as having early mild cognitive impairment (EMCI). The objective of this phase was to examine biomarkers in an earlier stage of disease. In 2011, as ADNI GO was ending, ADNI2 began with another $67 million in funding. ADNI2 assesses participants from the ADNI1/ADNI GO cohort in addition to the following new participants—150 elderly controls, 100 EMCI participants, 150 LMCI (late “mild cognitive impaitment”) participants and 150 mild AD patients.
Additional information on the ADNI study:
- The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception
- ADNI Update: January 2010 by Michael W. Weiner at Salpetriere in Paris